<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02193880</url>
  </required_header>
  <id_info>
    <org_study_id>UAB 1397</org_study_id>
    <nct_id>NCT02193880</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Trial for Alpha-Beta Depleted T-Cell Infusions Post Haplo Transplant</brief_title>
  <acronym>ABD</acronym>
  <official_title>Phase I/II Study of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ayman Saad</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of post-transplant
      cyclophosphamide and a post-transplant infusion of donor cells, that have been specially
      processed to remove alpha beta t-cells, in patients undergoing a haploidentical allogeneic
      stem cell transplant to help reduce the risk of relapse without increasing the risk of
      graft-versus-host disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transplant patients participating in this clinical trial will receive one of 3 standard
      pre-transplant chemotherapy preparative regimens as appropriate for their specific disease.
      They will then receive a standard non-manipulated donor stem cell infusion on transplant day
      (day 0) followed by cyclophosphamide (days +3 and +4) and an alpha-beta t-cell reduced donor
      stem cell infusion on day +7.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 9, 2014</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Actual">March 13, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>One-year progression-free survival.</measure>
    <time_frame>One year.</time_frame>
    <description>Progression-free survival will be calculated as time lapsed from transplant to either any death or disease relapse or progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute graft-versus-host disease.</measure>
    <time_frame>Within the first 100 days after transplant.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic graft-versus-host disease.</measure>
    <time_frame>From day +101 after transplant through one year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse.</measure>
    <time_frame>Within 2 years after transplant.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of overall survival.</measure>
    <time_frame>Within 2 years after transplant.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <condition>Graft-Versus-Host Disease</condition>
  <arm_group>
    <arm_group_label>Alpha-beta depleted T-cell infusion</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.</intervention_name>
    <description>Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.</description>
    <arm_group_label>Alpha-beta depleted T-cell infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neoplastic hematological disorder with indication of allogeneic transplant

          -  No available suitable HLA-matched donor

          -  Adequate cardiac, pulmonary, renal, and hepatic function

          -  Karnofsky performance status score greater than or equal to 70%

        Exclusion Criteria:

          -  Medication non-compliance

          -  No appropriate caregiver identified

          -  Uncontrolled medical or psychiatric disorder

          -  Active central nervous system (CNS) neoplastic involvement

          -  Known allergy to Dimethyl Sulfoxide

          -  HIV1 or HIV2 positive

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayman Saad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Medical Center (University of Alabama at Birmingham)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.uab.edu/medicine/bonemarrow/</url>
    <description>Click here for more information about the Bone Marrow Transplantation and Cell Therapy Program at the University of Alabama at Birmingham.</description>
  </link>
  <reference>
    <citation>Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, Fernandez-Vina M, Flomenberg N, Horowitz M, Hurley CK, Noreen H, Oudshoorn M, Petersdorf E, Setterholm M, Spellman S, Weisdorf D, Williams TM, Anasetti C. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007 Dec 15;110(13):4576-83. Epub 2007 Sep 4.</citation>
    <PMID>17785583</PMID>
  </reference>
  <reference>
    <citation>Alshemmari S, Ameen R, Gaziev J. Haploidentical hematopoietic stem-cell transplantation in adults. Bone Marrow Res. 2011;2011:303487. doi: 10.1155/2011/303487. Epub 2011 Jul 13.</citation>
    <PMID>22046559</PMID>
  </reference>
  <reference>
    <citation>Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006 Apr 27;354(17):1813-26. Review.</citation>
    <PMID>16641398</PMID>
  </reference>
  <reference>
    <citation>Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, Felicini R, Falcinelli F, Velardi A, Ruggeri L, Aloisi T, Saab JP, Santucci A, Perruccio K, Martelli MP, Mecucci C, Reisner Y, Martelli MF. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005 May 20;23(15):3447-54. Epub 2005 Mar 7.</citation>
    <PMID>15753458</PMID>
  </reference>
  <reference>
    <citation>Gale RP, Horowitz MM. Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1990 Jul;6 Suppl 1:94-7.</citation>
    <PMID>2390646</PMID>
  </reference>
  <reference>
    <citation>Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringd√©n O, Rozman C, Speck B, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990 Feb 1;75(3):555-62.</citation>
    <PMID>2297567</PMID>
  </reference>
  <reference>
    <citation>Ferrara JL, Yanik G. Acute graft versus host disease: pathophysiology, risk factors, and prevention strategies. Clin Adv Hematol Oncol. 2005 May;3(5):415-9, 428. Review.</citation>
    <PMID>16167015</PMID>
  </reference>
  <reference>
    <citation>Oevermann L, Handgretinger R. New strategies for haploidentical transplantation. Pediatr Res. 2012 Apr;71(4 Pt 2):418-26. doi: 10.1038/pr.2011.60. Epub 2012 Jan 25. Review.</citation>
    <PMID>22278184</PMID>
  </reference>
  <reference>
    <citation>Lamb LS Jr, Lopez RD. gammadelta T cells: a new frontier for immunotherapy? Biol Blood Marrow Transplant. 2005 Mar;11(3):161-8. Review. Erratum in: Biol Blood Marrow Transplant. 2005 Apr;11(4):318.</citation>
    <PMID>15744234</PMID>
  </reference>
  <reference>
    <citation>Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, Moretta A. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood. 2011 Jan 20;117(3):764-71. doi: 10.1182/blood-2010-08-264085. Epub 2010 Oct 1. Review.</citation>
    <PMID>20889923</PMID>
  </reference>
  <reference>
    <citation>Palmer JM, Rajasekaran K, Thakar MS, Malarkannan S. Clinical relevance of natural killer cells following hematopoietic stem cell transplantation. J Cancer. 2013;4(1):25-35. doi: 10.7150/jca.5049. Epub 2012 Dec 5.</citation>
    <PMID>23386902</PMID>
  </reference>
  <reference>
    <citation>Lamb LS Jr, Henslee-Downey PJ, Parrish RS, Godder K, Thompson J, Lee C, Gee AP. Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother. 1996 Oct;5(5):503-9.</citation>
    <PMID>8938522</PMID>
  </reference>
  <reference>
    <citation>Lamb LS Jr, Gee AP, Hazlett LJ, Musk P, Parrish RS, O'Hanlon TP, Geier SS, Folk RS, Harris WG, McPherson K, Lee C, Henslee-Downey PJ. Influence of T cell depletion method on circulating gammadelta T cell reconstitution and potential role in the graft-versus-leukemia effect. Cytotherapy. 1999;1(1):7-19. Erratum in: Cytotherapy. 1999;1(4):360.</citation>
    <PMID>19746645</PMID>
  </reference>
  <reference>
    <citation>Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S, Lamb LS. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 2007 Jun;39(12):751-7. Epub 2007 Apr 23.</citation>
    <PMID>17450185</PMID>
  </reference>
  <reference>
    <citation>Handgretinger R. New approaches to graft engineering for haploidentical bone marrow transplantation. Semin Oncol. 2012 Dec;39(6):664-73. doi: 10.1053/j.seminoncol.2012.09.007. Review.</citation>
    <PMID>23206843</PMID>
  </reference>
  <reference>
    <citation>Eto M, Mayumi H, Tomita Y, Yoshikai Y, Nishimura Y, Maeda T, Ando T, Nomoto K. Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice. J Immunol. 1991 Mar 1;146(5):1402-9.</citation>
    <PMID>1671578</PMID>
  </reference>
  <reference>
    <citation>Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol. 2002 May;128(2):255-66.</citation>
    <PMID>11985515</PMID>
  </reference>
  <reference>
    <citation>Luznik L, Engstrom LW, Iannone R, Fuchs EJ. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant. 2002;8(3):131-8.</citation>
    <PMID>11939602</PMID>
  </reference>
  <reference>
    <citation>Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001 Dec 1;98(12):3456-64.</citation>
    <PMID>11719388</PMID>
  </reference>
  <reference>
    <citation>Mayumi H, Umesue M, Nomoto K. Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology. 1996 Jul;195(2):129-39. Review.</citation>
    <PMID>8877390</PMID>
  </reference>
  <reference>
    <citation>Burroughs LM, O'Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, Jones RJ, Ambinder RF, Maris MB, Blume KG, Niederwieser DW, Bruno B, Maziarz RT, Pulsipher MA, Petersen FB, Storb R, Fuchs EJ, Maloney DG. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008 Nov;14(11):1279-87. doi: 10.1016/j.bbmt.2008.08.014.</citation>
    <PMID>18940683</PMID>
  </reference>
  <reference>
    <citation>Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bola√±os-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50. doi: 10.1016/j.bbmt.2008.03.005.</citation>
    <PMID>18489989</PMID>
  </reference>
  <reference>
    <citation>Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS, Jagasia MH, Ballen KK, Eapen M, O'Donnell PV; Blood and Marrow Transplant Clinical Trials Network. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011 Jul 14;118(2):282-8. doi: 10.1182/blood-2011-03-344853. Epub 2011 Apr 28.</citation>
    <PMID>21527516</PMID>
  </reference>
  <reference>
    <citation>Alvarnas JC, Brown PA, Aoun P, Ballen KK, Bellam N, Blum W, Boyer MW, Carraway HE, Coccia PF, Coutre SE, Cultrera J, Damon LE, DeAngelo DJ, Douer D, Frangoul H, Frankfurt O, Goorha S, Millenson MM, O'Brien S, Petersdorf SH, Rao AV, Terezakis S, Uy G, Wetzler M, Zelenetz AD, Naganuma M, Gregory KM; National Comprehensive Cancer Network. Acute lymphoblastic leukemia. J Natl Compr Canc Netw. 2012 Jul 1;10(7):858-914.</citation>
    <PMID>22773801</PMID>
  </reference>
  <reference>
    <citation>Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Weiss L, Winter JN, Yahalom J; NCCN Hodgkin Lymphoma. Hodgkin lymphoma. J Natl Compr Canc Netw. 2011 Sep 1;9(9):1020-58.</citation>
    <PMID>21917626</PMID>
  </reference>
  <reference>
    <citation>Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M; National Comprehensive Cancer Network. Non-Hodgkin's lymphomas, version 1.2013. J Natl Compr Canc Netw. 2013 Mar 1;11(3):257-72; quiz 273.</citation>
    <PMID>23486452</PMID>
  </reference>
  <reference>
    <citation>O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Lancet J, Maness LJ, Marcucci G, Martin MG, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Wang ES, Gregory KM, Naganuma M; National Comprehensive Cancer Network. Acute myeloid leukemia, version 2.2013. J Natl Compr Canc Netw. 2013 Sep 1;11(9):1047-55.</citation>
    <PMID>24029121</PMID>
  </reference>
  <reference>
    <citation>O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, Pinilla-Ibarz J, Reddy VV, Shah NP, Smith BD, Snyder DS, Wetzler M, Gregory K, Sundar H; Ntational comprehensive cancer network. Chronic Myelogenous Leukemia, Version 1.2014. J Natl Compr Canc Netw. 2013 Nov;11(11):1327-40.</citation>
    <PMID>24225967</PMID>
  </reference>
  <reference>
    <citation>Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, O'Donnell MR, Shami PJ, Stein BL, Stone RM, Thompson JE, Westervelt P, Wheeler B, Shead DA, Naganuma M. Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2013 Jul;11(7):838-74.</citation>
    <PMID>23847220</PMID>
  </reference>
  <reference>
    <citation>Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013 Feb;88(2):141-50. doi: 10.1002/ajh.23384. Review. Erratum in: Am J Hematol. 2013 May;88(5):437-45.</citation>
    <PMID>23349007</PMID>
  </reference>
  <reference>
    <citation>Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995 Jun;15(6):825-8. Review.</citation>
    <PMID>7581076</PMID>
  </reference>
  <reference>
    <citation>Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009 May 20;101(10):708-20. doi: 10.1093/jnci/djp079. Epub 2009 May 12. Review.</citation>
    <PMID>19436029</PMID>
  </reference>
  <reference>
    <citation>Luznik L, Bola√±os-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, Huff CA, Borrello I, Matsui W, Powell JD, Kasamon Y, Goodman SN, Hess A, Levitsky HI, Ambinder RF, Jones RJ, Fuchs EJ. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22;115(16):3224-30. doi: 10.1182/blood-2009-11-251595. Epub 2010 Feb 2.</citation>
    <PMID>20124511</PMID>
  </reference>
  <reference>
    <citation>Kaplan, EL, Meier, P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 53(282): 457-481, 1958.</citation>
  </reference>
  <reference>
    <citation>Gray, RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. The Annals of Statistics, 1141-1154, 1988.</citation>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2014</study_first_submitted>
  <study_first_submitted_qc>July 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2014</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Ayman Saad</investigator_full_name>
    <investigator_title>Assoc Prof Medicine M.D.</investigator_title>
  </responsible_party>
  <keyword>stem cell transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

